# A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy

> **NCT00001573** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (—)

## Conditions studied

- Glioma
- Sarcoma

## Interventions

- **DRUG:** SU101

## Key facts

- **NCT ID:** NCT00001573
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-03
- **Primary completion:** —
- **Final completion:** 2000-05
- **Target enrollment:** 30 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001573, "A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT00001573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*